(1-苄基-1H-咪唑-2-基-)-乙酸 | 123566-33-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (1-苄基-1H-咪唑-2-基-)-乙酸
• 英文名称: (1-benzylimidazol-2-yl)acetic acid
• 英文别名: 1-benzylimidazole-2-acetic acid；(1-Benzyl-1H-imidazol-2-yl)-acetic acid；2-(1-benzylimidazol-2-yl)acetic acid
• CAS: 123566-33-6
• 化学式: C₁₂H₁₂N₂O₂
• 分子量: 216.239
• InChiKey: PEXJLERUJWJFKU-UHFFFAOYSA-N

物化性质

• 沸点：
  427.2±28.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  (1-苄基-1H-咪唑-2-基-)-乙酸 在 磷酸 、 三氯化磷 作用下， 以 氯苯 为溶剂， 反应 3.0h， 以52%的产率得到1-hydroxy-2-(1-benzylimidazol-2-yl)ethylidene-1,1-bisphosphonic acid
  参考文献：
  名称：

  Highly Potent Geminal Bisphosphonates. From Pamidronate Disodium (Aredia) to Zoledronic Acid (Zometa)

  摘要：

  Bisphosphonates (BP) are pyrophosphate analogues in which the oxygen in P-O-P has been replaced by a carbon, resulting in a metabolically stable P-C-P structure. Pamidronate (1b, Novartis), a second-generation BP, was the starting point for extensive SAR studies. Small changes of the structure of pamidronate lead to marked improvements of the inhibition of osteoclastic resorption potency. Alendronate (1c, MSD), with an extra methylene group in the N-alkyl chain, and olpadronate (1h, Gador), the N,N-dimethyl analogue, are about 10 times more potent than pamidronate. Extending one of the N-methyl groups of olpadronate to a pentyl substituent leads to ibandronate (1k, Roche, Boehringer-Mannheim), which is the most potent close analogue of pamidronate. Even slightly better antiresorptive potency is achieved with derivatives having a phenyl group linked via a short aliphatic tether of three to four atoms to nitrogen, the second substituent being preferentially a methyl group (e.g., 4g, 4j, 5d, or 5r). The most potent BPs are found in the series containing a heteroaromatic moiety (with at least one nitrogen atom), which is linked via a single methylene group to the geminal bisphosphonate unit. Zoledronic acid (6i), the most potent derivative, has an ED50 of 0.07 mg/kg in the TPTX in vivo assay after sc administration. It not only shows by far the highest therapeutic ratio when comparing resorption inhibition with undesired inhibition of bone mineralization but also exhibits superior renal tolerability. Zoledronic acid (6i) has thus been selected for clinical development under the registered trade name Zometa. The results of the clinical trials indicate that low doses are both efficacious and safe for the treatment of tumor-induced hypercalcemia, Paget's disease of bone, osteolytic metastases, and postmenopausal osteoporosis.

  DOI：

  10.1021/jm020819i
• 作为产物：
  描述：

  1-苄基-2-甲基咪唑 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 20.0h， 生成 (1-苄基-1H-咪唑-2-基-)-乙酸
  参考文献：
  名称：

  Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine .beta.-hydroxylase. 4. Structure-activity relationships at the copper binding site

  摘要：

  Structure-activity relationships (SAR) were determined for novel multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1) by examining the effects upon in vitro inhibitory potencies resulting from structural changes at the copper-binding region of inhibitor. Attempts were made to determine replacement groups for the thione sulfur atom of the prototypical inhibitor 1-(4-hydroxybenzyl)imidazole-2-thione described previously. The synthesis and evaluation of oxygen and nitrogen analogues of the soft thione group demonstrated the sulfur atom to be necessary for optimal activity. An additional series of imidazole-2-thione relatives was prepared in an effort to probe the relationship between the pKa of the ligand group and inhibitory potency. In vitro inhibitory potency was shown not to correlate with ligand pKa over a range of approximately 10 pKa units, and a rationale for this is advanced. Additional ligand modifications were prepared in order to explore bulk tolerance at the enzyme oxygen binding site and to determine the effects of substituting a six-membered ligand group for the five-membered imidazole-2-thione ligand.

  DOI：

  10.1021/jm00164a051

文献信息

• Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective β3-adrenergic receptor agonists
  作者：Tatsuya Maruyama、Kenichi Onda、Masahiko Hayakawa、Norio Seki、Takumi Takahashi、Hiroyuki Moritomo、Takayuki Suzuki、Tetsuo Matsui、Toshiyuki Takasu、Itsuro Nagase、Mitsuaki Ohta

  DOI：10.1016/j.bmc.2009.03.044

  日期：2009.5

  In the search for potent and selective human β3-adrenergic receptor (AR) agonists as potential drugs for the treatment of obesity and noninsulin-dependent (type II) diabetes, a novel series of phenoxypropanolamine derivatives containing acetanilides were prepared and their biological activities were evaluated at the human β3-, β2-, and β1-ARs. Several of the analogues (21a, 21b, and 27a) exhibited

  在寻找有效和选择性的人β3-肾上腺素能受体（AR）激动剂作为治疗肥胖和非胰岛素依赖型（II型）糖尿病的潜在药物时，制备了一系列新的含乙酰苯胺的苯氧基丙醇胺衍生物，并对其生物学活性进行了评估。在人类β3-，β2-和β1-ARs中。几个类似物（21a，21b和27a）在β3-AR上显示出强大的激动活性。在本文所述的化合物中，发现N-甲基-1-苄基咪唑-2-基乙酰苯胺衍生物（21b）是最有效和选择性最强的β3-AR激动剂，EC 50β1-或β2-AR的值仅为0.28μM，且无激动活性。另外，在啮齿动物糖尿病模型中21b显示出显着的降血糖活性。
• Quinolinone derivatives as inhibitors of c-fms kinase
  申请人：Wall J. Mark

  公开号：US20050049274A1

  公开（公告）日：2005-03-03

  The invention is directed to compounds of Formulae I and II: wherein R 1 , R 2 , R 3 , R 5 , R 6 , Y 1 , Y 2 , Y 3 , Y 4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

  本发明涉及公式I和II的化合物：其中R1、R2、R3、R5、R6、Y1、Y2、Y3、Y4和X如规范中所示，以及其溶剂化物、水合物、互变异构体或药学上可接受的盐，它们能够抑制蛋白酪氨酸激酶，特别是c-fms激酶。
• QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1660087A2

  公开（公告）日：2006-05-31
• US7326788B2
  申请人：——

  公开号：US7326788B2

  公开（公告）日：2008-02-05
• [EN] QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE<br/>[FR] DERIVES DE QUINOLINONE EN TANT QU'INHIBITEURS DE C-FMS KINASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005009967A2

  公开（公告）日：2005-02-03

  The invention is directed to compounds of Formulae I and II, wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.